Last edition
News about "Nuvalent"
Jideytro Wins US Approval for ROS1-Positive NSCLC
Jideytro (zidesamtinib) has won US approval for previously treated ROS1-positive NSCLC, backed by ARROS-1 trial results showing durable responses.
Nuvalent | 24/07/2026 | By News Bureau | 107
GSK Enters Agreement to Acquire Nuvalent
GSK has agreed to acquire Nuvalent in a multi-product oncology deal that strengthens its lung cancer portfolio with two late-stage, potential best-in-class therapies—zidesamtinib and neladalkib—for non-small cell lung cancer.
Nuvalent | 10/06/2026 | By News Bureau | 257
Nuvalent Submits NDA to FDA for Neladalkib in Advanced ALK-Positive Lung Cancer
The investigational ALK inhibitor, backed by Phase I/II trial data, targets treatment-resistant non-small cell lung cancer and has received breakthrough and orphan drug designations.
Nuvalent | 08/04/2026 | By News Bureau | 152
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy